Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) reported Accumulated Expenses of $529000.0 for Q2 2025, up 47.8% quarter-over-quarter from $357923.6 in Q4 2024.
Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has 2 years of Accumulated Expenses data on file, last reported at $529000.0 in Q2 2025.
- Accumulated Expenses for Q2 2025 came in at $529000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $529000.0 (changed N/A YoY), and the FY2024 annual result was $352000.0, changed N/A from the prior year.
- Accumulated Expenses advanced to $529000.0 in Q2 2025 per ZYBT's latest filing, from $357923.6 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $529000.0 in Q2 2025 and troughed at $357923.6 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn |
| 10 | Zhengye Biotechnology Holding | 5.64 Mn | 6.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 529,000.00 |
| Dec 31, 2024 | 357,923.61 |